Loss of mitochondrial amidoxime-reducing component 1 (mARC1) prevents disease progression by reducing fibrosis in multiple mouse models of chronic liver disease

Abstract excerpt

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease is a prevalent disease that affects nearly one-third of the global population. Recent genome-wide association studies revealed that a common missense variant in the gene encoding mitochondrial amidoxime reducing component 1 (mARC1) is associated with protection from metabolic dysfunction-associated steatotic liver disease, all-cause cirrhosis,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug-Induced Hepatotoxicity and Protection
• Share to Liver Disease Diagnosis and Treatment
• Share to Mitochondrial Function and Pathology